Navigation Links
Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results
Date:8/17/2008

Zevalin(R) net sales of $15 million in 2008 on target; Potential label

expansion could further drive sales

SEATTLE, Aug. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported financial results for the quarter ended June 30, 2008. Total revenues for the quarter were $2.9 million compared to $20,000 for the second quarter of 2007 due primarily to sales of Zevalin(R) (Ibritumomab Tiuxetan), a commercial radiopharmaceutical that CTI acquired in December 2007. Net product sales of Zevalin reached $2.9 million in the second quarter of 2008.

"Given recent sales trends and growing physician interest, as well as recent Congressional action to extend reimbursement rates for Zevalin, we believe we are on track to reach $15 million in annual net sales for Zevalin this year," said James A. Bianco, M.D., CEO of CTI. "Furthermore, potential expansion of the label for Zevalin based upon data we recently obtained from Bayer Schering Pharma's First-line Indolent Trial (FIT) could support future sales growth. In addition to our progress with Zevalin, we now have OPAXIO's Marketing Authorization Application under review in Europe and expect results from our phase III pixantrone trial in the fourth quarter."

Recent Highlights

-- Entered into agreement with Bayer Schering Pharma for access to phase III Zevalin(R) FIT data for potential U.S. supplemental Biologics License Application (sBLA) to seek label expansion.

-- Scheduled meeting with the U.S. Food and Drug Administration (FDA) in September to discuss the possibility of filing a sBLA for use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma based on FIT trial data.

-- Legislation was passed by Congress that would continue the 2007 reimbursement methodology for therapeutic radioimmunotherapies for an additional 18 months with a start date of July
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... , ... Feb. 9 Reportlinker.com announces that a new ... The Clinical Laboratory Services Market (Growth Opportunities, ... http://www.reportlinker.com/p0176223/The-Clinical-Laboratory-Services-Market-Growth-Opportunities-Competitive-Analysis-and-Competitor-Profiles.html , Clinical laboratories are an essential part ...
... , SAN ... www.endpointclinical.com ), a leader in Integrated Voice Response (IVR)/Integrated Web ... platform that allows users to design and deploy clinical trial ... development time of clinical trials. This time and cost savings ...
... , , , , , ... 9 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE Amex: ... ("TCM") and Western Pharmaceuticals,based in Chengdu, China , today ... to Reform of Pricing Mechanism of Medicine,and Medical Services by ...
Cached Biology Technology:Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 2Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 3Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 4Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 5Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 6Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 7Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 8Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 9Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) 10endpoint Saves Money and Time for Medical Research Teams Through PULSE 2endpoint Saves Money and Time for Medical Research Teams Through PULSE 3Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services 2Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services 3
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... SANTA CRUZ, CA--Observations at submarine springs found along the ... preview of the possible fate of coral reef ecosystems ... pH (a measure of acidity) in the water around ... result from the widespread acidification of surface waters that ...
... Electronic infrastructures open new horizons for collaboration and acceleration ... such as scratchpads.eu , yield opportunities, ... newly collected data coming from different sources and working ... journal ZooKeys presenting the results ...
... FAIRFAX, Va.Researchers have published the largest single patient ... following patients with retrievable inferior vena cava (IVC) ... to the lungs. This study, which is important ... supports existing guidelines developed by the Society of ...
Cached Biology News:Submarine springs offer preview of ocean acidification effects on coral reefs 2Submarine springs offer preview of ocean acidification effects on coral reefs 3Electronic infrastructures accelerate biodiversity discoveries 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 3
... a 12 amino acid synthetic peptide whose sequence is derived ... is (amino to carboxy terminus): C - S(338) - ... Q - V - A - P - A(348). ... experiments with the polyclonal antibody that reacts with this product ...
... and easy operation of a wide range ... The software is fully secure and compliant ... 11 regulations, and compatible with user-created macros ... enables use in high-level research and development ...
... The PerkinElmer kit provides reagents for ... in serum and plasma samples using a ... samples are then neutralized and transferred to ... highly specific mouse monoclonal antibody to HIV-1 ...
... is an automated solution for scheduling, performing ... testing for all pipettes and liquid handling ... balance Supports all gravimetric calibration ... 12650, ISO 9000, NCCLS and GLP requirements ...
Biology Products: